close
MENU
Hot Topic Hawke’s Bay
How to guide
How to guide
Home
The NBR List
NBR View
NBR Marketplace

Categories

General Business Investment Economics Te Ao Māori Politics Infrastructure Australia Tech & Innovation Finance Law Professional Services Primary Industries Retail Property Deals Aviation News Comings & Goings

Analysis

All Economy Matters Edwards on Politics Hunter’s Corner Last Word Margin Call On the Money Shoeshine Underarm NBR Focus

Featured

Podcasts Audio Articles Entrepreneurs Your Business Beehive Banter Morning Brew Toil & Trouble NZ Aviation News Back Issues Market Outlook Dollars & Sense Private Bin Opinion (Archive) NBR Radar (Archive) NBR Rich List (Archive)
Hot Topic Hawke’s Bay
Investment
3 mins to read

AFT poised for new product launches in New Zealand and abroad

The pharmaceutical company doesn’t want to stop with Maxigesic.

AFT Pharmaceutical Managing director Dr Hartley Atkinson

Kate McVicar Fri, 05 Aug 2022

AFT Pharmaceuticals (AFT) is poised for a number of new product launches domestically and abroad. 

Operating regions New Zealand and Australia are set for 12 and 24 new product launches over the 2023 financial year respectively, with five additional countries in Asia scheduled for Maxigesic IV

Want to read more? It's easy.

Choose your best value subscription option

Student

Exclusive offer for uni students studying at a New Zealand university (valued at $499).
View terms and conditions.
Individual
Group membership
NBR Marketplace

Yearly Premium Online Subscription

NZ$499.00 / yearly

Monthly Premium Online Subscription

NZ$44.95 / monthly

Smartphone Only Subscription

NZ$24.95 / monthly

Premium Group Membership 10 Users

NZ$350+GST / monthly

$35 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$600+GST / monthly

$30 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1250+GST / monthly

$25 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$1875+GST / monthly

$18.75 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$499.00 / yearly

Already have an account? Login
Kate McVicar Fri, 05 Aug 2022
Contact the Writer: kate@nbr.co.nz
News tip? Question? Typo? Let us know: editor@nbr.co.nz
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Tags
AFT Pharmaceuticals AFT Hartley Atkinson
Company profile
Powered by:
Change:
Price
Previous Close
Turnover
Movement
Volume
Avg Daily Volume
Daily High
Daily Low
52 Week High
52 Week Low
Related News
General Business

Why Kiwi drug maker is not calling it quits on Pascomer
Investment

Operating profit for AFT Pharmaceuticals nearly doubles
Investment

Judge shuts down appeal on AFT advertising decision
Investment

AFT Pharmaceuticals retains operating profit guidance
Investment

AFT Pharmaceuticals half-year earnings up despite Covid
General Business
2

Covid clips the wings of AFT Pharmaceuticals in year-end results

Company profile
Powered by:
Change:
Price
Previous Close
Turnover
Movement
Volume
Avg Daily Volume
Daily High
Daily Low
52 Week High
52 Week Low
Related News
General Business

Why Kiwi drug maker is not calling it quits on Pascomer
Investment

Operating profit for AFT Pharmaceuticals nearly doubles
Investment

Judge shuts down appeal on AFT advertising decision
Investment

AFT Pharmaceuticals retains operating profit guidance
Investment

AFT Pharmaceuticals half-year earnings up despite Covid
General Business
2

Covid clips the wings of AFT Pharmaceuticals in year-end results

AFT poised for new product launches in New Zealand and abroad
Investment,
95169
true
Subscribe Login